Prostate cancer patients receiving care at hospitals that are part of a special drug-pricing program were more likely to stick to their prescription drug therapy than patients at other hospitals, according to a study from researchers at the University of Michigan’s Rogel Cancer Center and Institute for Healthcare Policy and Innovation.